Determinants of Glycemic Control with Automated Insulin Delivery in adults living with type 1 diabetes: A 12-Month Sub-Analysis of the French OB2F Registry.

Authors

Michael Joubert, Jean-Baptiste Julla, Eric Renard, Sandrine Lablanche, Agnès Sola, Emmanuel Cosson, Jean-Paul Donnet, Emmanuel Sonnet, Anne Vambergue, Salah Fendri, Lucien Marchand, Amal Lemoine, Laurence Kessler, Mathieu Giraud, Isabela Banu, Elise Pinto Da Rocha, Camille Vatier, Françoise Plat, Aurélie Carlier, Jean-François Gautier, Jean-Pierre Riveline, OB2F Study Group

Published in

Annales d'endocrinologie. Pages 102600. Jul 18, 2026. Epub Jul 18, 2026.

Abstract

To identify baseline determinants of achieving international continuous glucose monitoring (CGM) targets after 12 months of automated insulin delivery (AID) in adults with type 1 diabetes.
This predefined sub-analysis of the nationwide French OB2F registry included adults with type 1 diabetes initiating MiniMed 780G or Tandem Control-IQ in 2022. Participants required ≥14 consecutive days of CGM data at baseline and 12 months. The primary outcome was achievement of combined CGM targets at 12 months, defined as TIR >70% and TBR <4%. Baseline predictors were assessed using multivariable logistic regression.
Among 1,058 adults, 43% achieved combined CGM targets at 12 months (52% of MiniMed 780G users and 36% of Tandem Control-IQ users). Better baseline metabolic control, including higher TIR and lower HbA1c, TAR, GMI, and glucose variability, was independently associated with target achievement across both systems. Lower baseline TBR predicted target achievement only in MiniMed 780G users. GRI improved in both systems, from 44.1±19.4 to 30.2±13.6 with MiniMed 780G and from 49.4±20.0 to 36.7±14.9 with Tandem Control-IQ.
Baseline glycaemic profile is the main determinant of achieving international CGM targets after AID initiation in adults with type 1 diabetes, despite substantial improvement in those with poorer baseline control.

PMID:
42471113
Bibliographic data and abstract were imported from PubMed on 19 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.